48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohortAlfonso Cabello, Miguel Górgolas, Jorge Vergas et al.|PLoS ONE|2022Cited by 20
Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA StudyAlfonso Cabello, Federico Pulido, Juan Carlos López Bernardo de Quirós et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2025Cited by 1